PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: A new strategy to restrain cholangiopathy in primary biliary cirrhosis

Medical Molecular Morphology

Volumn 46, Issue 3, 2013, Pages 153-159

  Nozaki, Yusuke ^a,b   Harada, Kenichi ^a   Sanzen, Takahiro ^b   Nakanuma, Yasuni ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

15d PGJ2; Cholangiopathy; MRL lpr mouse; Peroxisome proliferator activated receptor; Primary biliary cirrhosis

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CHOLANGITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; IN VIVO STUDY; MACROPHAGE; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NONHUMAN; PORTAL VEIN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; CHOLANGITIS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LIVER CIRCULATION; LIVER CIRRHOSIS, BILIARY; MALE; MICE; MICE, TRANSGENIC; PORTAL SYSTEM; PPAR GAMMA; PROSTAGLANDIN D2;

EID: 84884591441     PISSN: 18601480     EISSN: 18601499     Source Type: Journal    
DOI: 10.1007/s00795-013-0017-0     Document Type: Article

References (37)

1. Nakanuma Y, Ohta G (1979) Histometric and serial section observations of the intrahepatic bile ducts in primary biliary cirrhosis. Gastroenterology 76:1326-1332
2. Kaplan MM, Gershwin ME (2005) Primary biliary cirrhosis. N Engl J Med 353:1261-1273
3. Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, Sakamoto N, Matsushita S, Tanaka A, Worman HJ, Gershwin ME, Harada M (2003) Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology 124:1915-1925
4. Harada K, Tsuneyama K, Sudo Y, Masuda S, Nakanuma Y (2001) Molecular identification of bacterial 16S ribosomal RNA gene in liver tissue of primary biliary cirrhosis: is Propionibacterium acnes involved in granuloma formation? Hepatology 33:530-536
5. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, Kurth MJ, Gershwin ME (2003) Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic- metabolizing bacterium. Hepatology 38:1250-1257
6. Selmi C, De Santis M, Cavaciocchi F, Gershwin ME (2010) Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis. Dis Markers 29:287-299
7. Selmi C, Lleo A, Pasini S, Zuin M, Gershwin ME (2009) Innate immunity and primary biliary cirrhosis. Curr Mol Med 9:45-51
8. Gershwin ME, Mackay IR (2008) The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47:737-745
9. Harada K, Ohira S, Isse K, Ozaki S, Zen Y, Sato Y, Nakanuma Y (2003) Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab Invest 83:1657-1667
10. Harada K, Isse K, Nakanuma Y (2006) Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction. J Clin Pathol 59:184-190
11. Hiramatsu K, Harada K, Tsuneyama K, Sasaki M, Fujita S, Hashimoto T, Kaneko S, Kobayashi K, Nakanuma Y (2000) Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis. J Hepatol 33:9-18
12. Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y (2005) Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology 41:1329-1338
13. Yamamoto-Furusho JK, Penaloza-Coronel A, Sanchez-Munoz F, Barreto-Zuniga R, Dominguez-Lopez A (2011) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) expression is downregulated in patients with active ulcerative colitis. Inflamm Bowel Dis 17:680-681
14. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341-1349
15. Peyrin-Biroulet L, Beisner J, Wang G, Nuding S, Oommen ST, Kelly D, Parmentier-Decrucq E, Dessein R, Merour E, Chavatte P, Grandjean T, Bressenot A, Desreumaux P, Colombel JF, Desvergne B, Stange EF, Wehkamp J, Chamaillard M (2010) Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 107:8772-8777
16. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P (2003) Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124:1265-1276
17. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383-389
18. Wada K, Nakajima A, Blumberg RS (2001) PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 7:329-331
19. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813-819
20. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995) 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83:803-812
21. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N (2001) Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120:460-469
22. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193:827-838
23. Boyault S, Simonin MA, Bianchi A, Compe E, Liagre B, Mainard D, Becuwe P, Dauca M, Netter P, Terlain B, Bordji K (2001) 15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett 501:24-30
24. Tsuneyama K, Nose M, Nisihara M, Katayanagi K, Harada K, Nakanuma Y (2001) Spontaneous occurrence of chronic non-suppurative destructive cholangitis and antimitochondrial autoantibodies in MRL/lpr mice: possible animal model for primary biliary cirrhosis. Pathol Int 51:418-424
25. Nose M, Nishihara M, Fujii H (2000) Genetic basis of the complex pathological manifestations of collagen disease: lessons from MRL/lpr and related mouse models. Int Rev Immunol 19:473-498
26. Ohba K, Omagari K, Murase K, Hazama H, Masuda J, Kinoshita H, Isomoto H, Mizuta Y, Miyazaki M, Murata I, Kohno S (2002) A possible mouse model for spontaneous cholangitis: serological and histological characteristics of MRL/lpr mice. Pathology 34:250-256
27. Harada K, Sato Y, Itatsu K, Isse K, Ikeda H, Yasoshima M, Zen Y, Matsui A, Nakanuma Y (2007) Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia. Hepatology 46:1146-1154
28. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82
29. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
30. Lefebvre M, Paulweber B, Fajas L, Woods J, McCrary C, Colombel JF, Najib J, Fruchart JC, Datz C, Vidal H, Desreumaux P, Auwerx J (1999) Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 162:331-340
31. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403:103-108
32. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y (1995) HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 181:1835-1845
33. Iwata Y, Bostrom EA, Menke J, Rabacal WA, Morel L, Wada T, Kelley VR (2012) Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice. J Immunol 188:4568-4580
34. Okai T, Mouri H, Yamaguchi Y, Nakanuma Y, Sawabu N (2002) Beneficial hepatic effect of troglitazone in a patient with antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 97:209-210
35. Hisada S, Shimizu K, Shiratori K, Kobayashi M (2005) Peroxisome proliferator-activated receptor gamma ligand prevents the development of chronic pancreatitis through modulating NF-kappaB-dependent proinflammatory cytokine production and pancreatic stellate cell activation. Rocz Akad Med Bialymst 50:142-147
36. van Westerloo DJ, Florquin S, de Boer AM, Daalhuisen J, de Vos AF, Bruno MJ, van der Poll T (2005) Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol 166: 721-728
37. Zingarelli B, Cook JA (2005) Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23:393-399